Understanding patients risks of adverse outcomes and their rate of disease progression, and how this varies according to patient characteristics is essential in understanding the benefits of intervention. In this session we will explore how large real world data sets are being used to quantify these outcomes using examples from oncology and rheumatology. We will also hear how novel approaches to accessing and analysing data may facilitate use of datasets that must be stored in different geographical locations.